Biography and Research Information
OverviewAI-generated summary
Yusra B. Medik's research investigates the interplay between the gut microbiome, immune responses, and therapeutic outcomes, particularly in the context of cancer and autoimmune diseases. Her work has explored how dietary fiber and probiotics can influence the efficacy of melanoma immunotherapy. Medik has also focused on drug delivery systems, including the co-delivery of chemotherapy agents via dual-drug loaded nanoparticles to enhance chemoradiotherapy for non-small cell lung cancer models. Further research has examined the mechanisms of intestinal toxicity associated with immune checkpoint blockade, identifying the roles of IL-6 and myeloid infiltration. Additionally, her studies have contributed to understanding the immune regulation of Type 1 Diabetes through bioengineered beta cell vaccines and the protective functions of STAT3 in hematopoietic stem cells against autocrine type-I interferon responses. Medik's scholarship metrics include an h-index of 8, with 27 publications and 1,261 citations.
Metrics
- h-index: 8
- Publications: 27
- Citations: 1,292
Selected Publications
-
Stem Cell Origin of Cancer: Biological Principles and Clinical Strategies for Chemoprevention and Maintenance Therapy in Cancer Care (2025)
-
Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers. (2025)
Collaboration Network
Top Collaborators
Laura M. Kahn
The University of Texas MD Anderson Cancer Center (US)
11 shared publications
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Regulation and function of Id2 in plasmacytoid dendritic cells
Showing 5 of 11 shared publications
Yifan Zhou
The University of Texas MD Anderson Cancer Center (US)
10 shared publications
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Regulation and function of Id2 in plasmacytoid dendritic cells
Showing 5 of 10 shared publications
Rachel L. Babcock
The University of Texas Health Science Center at Houston (US)
10 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Regulation and function of Id2 in plasmacytoid dendritic cells
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Showing 5 of 10 shared publications
Bhakti Patel
The University of Texas MD Anderson Cancer Center (US)
9 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Regulation and function of Id2 in plasmacytoid dendritic cells
- STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
Showing 5 of 9 shared publications
Taylor T. Chrisikos
The University of Texas MD Anderson Cancer Center (US)
7 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- Regulation and function of Id2 in plasmacytoid dendritic cells
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Showing 5 of 7 shared publications
Stephanie S. Watowich
The University of Texas MD Anderson Cancer Center (US)
7 shared publications
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Regulation and function of Id2 in plasmacytoid dendritic cells
- STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
- STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions
Showing 5 of 7 shared publications
Allison M. Dyevoich
5 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Outcome of concurrent treatment with a-CTLA4 and metronidazole in murine model of colon adenocarcinoma.
- Regulation and function of Id2 in plasmacytoid dendritic cells
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Josué E. Pineda
The University of Texas Health Science Center at Houston (US)
5 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
- STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions
Andrew Z. Wang
4 shared publications
- Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models
- Immune Checkpoint‐Bioengineered Beta Cell Vaccine Reverses Early‐Onset Type 1 Diabetes
- Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo
- Correction to “Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo”
Alexandria P. Cogdill
4 shared publications
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Sarah B. Johnson
4 shared publications
- Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Elizabeth M. Park
The University of Texas MD Anderson Cancer Center (US)
4 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response
- STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Aron Y. Joon
The University of Texas MD Anderson Cancer Center (US)
4 shared publications
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Abstract 5545: Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
- Bilateral germ cell tumor of the testis (TGCT): Implications for a stem cell versus genetic origin of cancers.
Xi Tian
3 shared publications
- Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models
- Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo
- Correction to “Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo”
Feifei Yang
3 shared publications
- Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models
- Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo
- Correction to “Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo”
Similar Researchers
Based on overlapping research topics
Erbin Dai
National Center for Toxicological Research
Gut microbiota and health
Nanoparticle-Based Drug Delivery
Cancer Treatment and Pharmacology
Chandra Mohan Reddy Muthumula
National Center for Toxicological Research
Gut microbiota and health
Nanoparticle-Based Drug Delivery
Cancer Treatment and Pharmacology
Marufa Rumman
National Center for Toxicological Research
Gut microbiota and health
Immune Response and Inflammation
Diet and metabolism studies
Zachary McConnell
University of Arkansas at Fayetteville
Nanoparticle-Based Drug Delivery
Cancer Treatment and Pharmacology
Drug Delivery Systems
Nabeel Alwan
University of Arkansas at Little Rock
Nanoparticle-Based Drug Delivery
Cancer Treatment and Pharmacology
Drug Delivery Systems
Arisha Ishtiaq
University of Arkansas at Little Rock
Nanoparticle-Based Drug Delivery
Cancer Treatment and Pharmacology
Drug Delivery Systems